Moderna reports positive Phase 3 results for its personalized melanoma vaccine with Merck’s Keytruda
Moderna announced that its personalized cancer vaccine, intismeran autogene, met recurrence‑free survival goals in a Phase 3 trial for melanoma when combined with Merck’s Keytruda. The company is now preparing an FDA submission with Merck. The news has driven the stock up about 600% this year, pushing the share price to roughly $242 and a market value near $96 billion.
Why it matters
The trial success has sparked strong investor enthusiasm, lifting Moderna’s share price far above the average analyst price target of $123, but the personalized nature of the product may limit rapid revenue growth. Analysts note that the company’s recent revenue of $1.94 billion and net loss of $2.82 billion highlight the financial risk of the oncology pivot.
Key facts
- 1Moderna’s personalized cancer vaccine intismeran autogene achieved positive Phase 3 results for melanoma in combination with Merck’s Keytruda, meeting recurrence‑free survival goals. finance.yahoo.com
- 2Moderna and Merck are moving toward preparing an FDA submission following the trial results. abcmoney.co.uk
- 3Moderna’s stock has risen about 600% this year, trading around $242 per share as of October 20, 2026. abcmoney.co.uk
- 4The company’s market capitalization is roughly $96 billion. abcmoney.co.uk
- 5Average analyst price target is about $123 per share. abcmoney.co.uk
- 6Annual revenue for the most recent period was $1.94 billion and net loss was $2.82 billion. abcmoney.co.uk
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.